



# Guidance on Expiring & Expired Therapeutics

Last Updated May 25, 2022

**As a COVID-19 Therapeutics Provider in the Commonwealth of Virginia, you are required to operate in accordance with COVID-19 therapeutic expired and expiring product guidance. Carefully review the information below to ensure your site is prepared to dispose of therapeutics in compliance with Virginia Department of Health (VDH) and Health and Human Services (HHS) regulations.**

## Expiring & Expired Product Guidelines for Therapeutics in HPoP

- Providers can report wastage in the Health Partner Order Portal (HPoP) for the following therapeutics: EVUSHELD, Bebtelovimab, Paxlovid, Renal Paxlovid, and Lagevrio (Molnupiravir)
  - Wastage reporting is required if the therapeutics in your inventory expire, are damaged, experience temperature excursion, or another reason that prohibits them from being used or redistributed
- Unused products that are still in date should **not** be discarded/destroyed and reported as wastage
  - If your facility has soon-expiring products on-hand that will not be used, consider an interfacility transfer to another site to avoid wastage
  - *VDH is in process of developing a redistribution process to redistribute unexpired products*
- For information regarding how to report therapeutic wastage in HPoP, please refer to our HPoP Job Aid [here](#)
- If you are having challenges with reporting or have questions, please contact [COVID19Therapeutics@vdh.virginia.gov](mailto:COVID19Therapeutics@vdh.virginia.gov) for assistance

## Expiring & Expired Product Guidelines for Legacy Therapeutics

- Legacy therapeutics are therapeutics that have had their Emergency Use Authorization (EUA) amended due to low efficacy against current variants of COVID-19
  - *\*As of 5/25/22, sotrovimab, BAM/ETE and REGEN-COV have had their EUAs amended to exclude them from use in any U.S. region. Limitations on use of these products may be revised in the future.*
  - These therapeutics are **not** available to report as wastage in HPoP
- VDH recommends that providers contact the manufacturers regarding returning undamaged legacy therapeutics:
  - **Bamlovimab (BAM) and Bamlovimab/Etesevimab (BAM/ETE)**
    - Visit [www.lillytrade.com](http://www.lillytrade.com) for guidance on returning product
  - **REGEN-COV**
    - Call Regeneron Medical Information at 1-844-REGN-MID (1-844-734-6643) to return product
  - **Sotrovimab**
    - Visit [www.gsk-ecs.com](http://www.gsk-ecs.com) for guidance on returning product
- Reconstituted (diluted) product should **not** be returned and should be treated as waste per your facility's SOP (Standard Operating Procedures)